Hepatitis C virus infection

Related records

Broader conditions (17)

• Digestive system disorder
• Digestive system infectious disorder
• Disease
• Disease by body system or component
• Disease by developmental or physiological process
• Disease by etiologic mechanism
• Disease of primarily extrinsic mechanism
• Endocrine system disorder
• Hepatitis
• Hepatobiliary disorder
• Human disease
• Infectious disease
• Inflammatory disease
• Liver disorder
• Primary viral infectious disease
• Viral hepatitis
• Viral infectious disease

Narrower conditions (2)

• Acute hepatitis C virus infection
• Chronic hepatitis C virus infection

Trials (1,739)

• "Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
• "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"
• "Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"
• "Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt
• 12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.
• 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
• 14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
• 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection
• 3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals
• 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8
• 4-Methylumbelliferone as a Treatment for Chronic HBV/HCV
• 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C
• A 5-year Observational Follow-up Study to Describe Treatment Patterns in Real World of HCV Patients in China.
• A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir
• A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C
• A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
• A Community-based Intervention Among Active Drug Users in Montpellier
• A Community-based, Behavioral Intervention to Improve Screening for Hepatitis C Among High-risk Young Adults in Wisconsin
• A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)
• A Comprehensive HBsAg-positive Patients Centered Screening Strategy

Approved drugs (6)

• Dasabuvir sodium monohydrate
• Ledipasvir
• Ombitasvir
• Paritaprevir
• Ritonavir
• Sofosbuvir

Drugs in development (224)

• 4'-azidocytidine Phase 1
• Abacavir Phase 1
• ABT-072 Phase 2
• ABT-384 Phase 2
• Adafosbuvir Phase 1
• Adefovir dipivoxil Phase 2
• Ademetionine Phase 2
• Albinterferon alfa-2B Phase 2
• Aldesleukin Phase 1
• Alisporivir Phase 3
• Allantoin Phase 3
• Amantadine Phase 2
• Amantadine hydrochloride Phase 2
• Asunaprevir Phase 3
• Atorvastatin Phase 2
• Avatrombopag Phase 2
• Avenciguat Phase 2
• AZD-7295 Phase 1
• Balapiravir Phase 1
• Balapiravir hydrochloride Phase 1

Other linked drugs (22)

• Acetylcysteine
• Colchicine
• Dexamethasone
• Fosamprenavir
• Fosamprenavir sodium
• Hydrocortisone
• Insulin human
• Keyhole limpet hemocyanin
• Lamivudine
• Methylprednisolone
• Methylprednisolone acetate
• Naloxone hydrochloride dihydrate
• Nevirapine
• Prednisolone
• Rimantadine
• Rituximab
• Tacrolimus
• Taurursodiol
• Tenofovir
• Triamcinolone